aeruginosa—one of the most prevalent infection-causing bacteria in cystic fibrosis—and evidence of phage-resistant bacteria having reduced pathogenicity in the nine adults treated with this ...

The US government has provided almost $24 million in funding to Locus Biosciences to support a mid-stage trial of LBP-EC01, a CRISPR-engineered bacteriophage therapy in development for resistant ...